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Abstract: Idiopathic pulmonary arterial hypertension (IPAH) is a rare but severe disease with the
elevated blood pressure in the pulmonary arteries without a known trigger of vascular remodelling.
It leads to the right heart failure with reduced survival. Changes in the immunological landscape of
the lungs and the periphery are common in IPAH patients, suggesting an immune system dysfunction.
A cohort of 25 IPAH patients was enrolled in our study to investigate a link between the patient’s
clinical status, immune parameters of the blood, and the Epstein–Barr virus (EBV) infection. We
found significant alterations of the patients’ peripheral blood parameters. Therein, T lymphocytes
and NK cell counts were decreased in the IPAH patients’ blood, while the proportion of regulatory
T cells was increased. Additionally, levels of proinflammatory cytokines interleukin-6 (IL-6), IL-2,
and interferon-gamma (IFN-γ) were elevated. We identified a weak correlation between EBV loads
and IPAH patients’ clinical state (r = 0.54) and between EBV loads and overexpression of PD-1
on helper T cells (r = 0.56). We speculate that a significant dysregulation of the immune system
homeostasis observed in IPAH patients may contribute to increased susceptibility of those patients to
EBV infection, yet further longitudinal studies are required to characterize this relation in detail.
Keywords: idiopathic pulmonary arterial hypertension; IPAH; cardiovascular disease; Epstein–Barr
virus; EBV; PD-1; hypertension immunopathology
1. Introduction
Idiopathic pulmonary arterial hypertension (IPAH) is a sporadic disease that is associated with
high morbidity and mortality rates. The disease affects the precapillary pulmonary vasculature and
is characterised by a persistent hypertension in the pulmonary artery exceeding 25 mmHg, with a
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pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg and pulmonary vascular resistance (PVR) >
3 Wood units (WU) [1]. The trigger of the disease is not defined, and when untreated, the disease
may lead to the right ventricular dilatation resulting in right heart failure and eventually death of
the patient [2]. Based on the symptoms severity and haemodynamic parameters, IPAH patients are
classified into one of four WHO functional classes, with class I being the most benign and class IV
comprising rapidly progressing patients with a high mortality risk and poor haemodynamic results [3].
Studies have shown that the immune landscape of patients suffering from IPAH is severely
impacted, both in the lungs and in the periphery [4,5]. Significant changes in the cytokine profiles,
such as IL-1β, IL-6, IL-8, MCP-1, RANTES, and TNF, were observed in IPAH patients when compared
to healthy controls [5]. Indeed, some of the cytokines, e.g., IL-6, have been proposed as prognostic
markers in assessing the clinical state and the survival of the patients [6]. It has also been observed that
the cellular composition of the immune compartment can be altered in the IPAH patients. For example,
lung tissue affected by IPAH has been shown to be infiltrated by CD4+ and CD8+ T lymphocytes [7,8],
while the proportion of regulatory T cells (Treg) in the periphery was elevated [8]. Besides the cytokine
markers, a significant deficiency in CD8+ T cells, as well as NK cells has been identified as a sign of
deterioration of an IPAH patient’s status [9].
PD-1 (programmed cell death protein 1), known also as CD279, is an immune checkpoint protein
expressed on the surface of T cells and certain B cells [10]. PD-1 on T cells serves as an inhibitor of
the activating signals coming from TCR (T-cell receptor) and CD28, while PD-1-expressing B cells
are regulatory toward T-cell responses [11,12]. Expression of PD-1 on T cells is induced during their
activation, and PD-1 is abundantly present on the surface of activated and exhausted T cells [13]. PD-1
induces attenuation of the immune activation by interacting with two ligands: PD-L1 and PD-L2
(CD274 and CD273, respectively). PD-L1 is widely distributed in the body, being detected on T cells, B
cells and antigen-presenting cells, as well as in non-immune tissues such as endothelium, placenta,
and pancreatic islets [12]. PD-1/PD-L1 interaction may lead to inhibition of lymphocyte activation and
proliferation and facilitates expansion of Treg. As a consequence, such an interaction limits tissue
destruction that could occur during prolonged and uncontrolled inflammation, and thus, it protects
the organism from auto-aggression [14,15].
Some viruses have been implicated in PAH development. Infection with human immunodeficiency
virus (HIV) and chronic, active Epstein–Barr virus (EBV) infection are among the risk factors for
developing PAH [16,17]. Moreover, a link between chronic, active EBV infection and development of
PAH has been reported. Interestingly, the involvement of other viruses, such as human herpesvirus
8 (HHV-8), remains controversial. Some authors identified HHV-8 in samples obtained from PAH
patients [18,19], while others found no link between HHV-8 infection and development of PAH [20,21].
In our study, we analysed blood samples obtained from 25 IPAH patients from various WHO
functional classes of IPAH and 20 corresponding healthy controls. Haemodynamic parameters of
the IPAH cohort, the EBV loads of patients and controls as well as their anti-EBV serological status
were recorded. We noted that the IPAH patients were characterised by highly elevated levels of
proinflammatory cytokines in the plasma. Proportions of CD4+ and CD8+ T cells, as well as NK cells
in the blood, were decreased. At the same time, the number of Tregs was elevated, and PD-1 and PD-L1
were overexpressed on the surface of T and B lymphocytes. We found a weak but significant correlation
between EBV copy number and the IPAH class and a link between EBV loads and expression of PD-1
molecules on CD4+ T cells. We have found that all EBV-positive IPAH patients had the antibodies
indicating a past EBV infection; therefore, the observed positive EBV DNA test result suggests a
viral reactivation. This outcome may suggest that the immune system dysregulation often observed
during PAH may facilitate EBV reactivation, which may in turn exacerbate cardiovascular symptoms
of IPAH patients.
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2. Materials and Methods
2.1. Patients and Controls
We included 25 treatment-naïve, newly diagnosed patients with IPAH (10 men and 15 women)
and 20 healthy volunteers (8 men and 12 women) matched for sex and age, who served as a control
group. IPAH was diagnosed according to the criteria of the European Society of Cardiology and
the European Respiratory Society [3]. The patients were recruited with the following inclusion
criteria: no immunomodulatory treatment; no signs of infection at least three months before enrolment;
no blood transfusion; no history of autoimmune, neoplastic, or allergic diseases. In patients with
pulmonary hypertension, the functional class of heart failure was determined according to WHO
criteria [3]. Each patient underwent complete blood count and natriuretic peptide (BNP) concentration
assessments and a six-minute walk test. Basic laboratory tests were performed in the Alab laboratory
of the Independent Public Clinical Hospital in Lublin. An echocardiographic examination of
the heart (ECHO) was performed using a Phillips iE33 instrument. Cardiac catheterisation was
carried out in the Haemodynamics Laboratory of the Independent Public Clinical Hospital and the
Cardiology Department of the Provincial Specialist Hospital in Lublin, according to haemodynamic
and angiographic assessment standards recommended by the Polish Cardiac Society [22]. The study
was approved by the Ethics Committee of the Medical University of Lublin (KE-0254/309/2016)), and
written informed consent was obtained from all participants. This study was conducted in accordance
with the Helsinki Declaration.
2.2. Preparation of Material
We collected 15 mL of peripheral blood in EDTA-coated tubes (Sarstedt, Nümbrecht, Germany).
Blood from the EDTA-coated tubes was used to isolate peripheral blood mononuclear cells (PBMC) and
plasma by density gradient centrifugation at 400 g for 30 min, no brake. Briefly, 5 mL of the whole blood
diluted with 5 mL of saline was applied on 5 mL of Ficoll-Paque™ (Milteny Biotec, Bergisch-Gladbach,
Germany). The PBMC layer was harvested; the cells were counted, and their viability was checked with
trypan blue (0.4% trypan blue solution; Sigma Aldrich, Hamburg, Germany). Only PBMC samples
with viability ≥95% were used. Plasma from the tubes with EDTA anticoagulant was stored at −80 ◦C
until assayed.
2.3. Immunophenotyping
Immunophenotyping was performed using flow cytometry as previously described [23,24].
Cells were stained with a combination of monoclonal antibodies conjugated with different fluorochromes
to determine the proportion of the specific cell types and the expression of PD-1 and PD-L1 on their
surface. Percentages of PD-1-positive and PD-L1-positive T and B lymphocytes were measured
using combinations of the following monoclonal antibodies: CD45/FITC, CD14/PE, CD3/CyChrome,
CD19/FITC, CD4/FITC, CD8/FITC, CD279 (PD-1)/PE, and CD274 (PD-L1)/PE. Percentages of NK and
natural killer T-like (NKT-like) cells were identified using CD3/FITC, CD16CD56/PE, and CD45/PerCP
monoclonal antibodies, which allowed for the simultaneous assessment of CD3+ T lymphocytes
and NK (CD16+CD56+) cells. CD19 expression was used as B cell marker. During analysis, the
CD3+CD16+CD56+ (NKT-like cell) population was also determined. Monoclonal antibodies were
purchased from BD Biosciences, USA. Additionally, the number of CD4+ CD25high FOXP3+ Treg cells
in the CD4+ T lymphocyte subpopulation was determined using the Human Treg Flow kit (FOXP3
Alexa Fluor 488/CD4 PE-Cy5/CD25 PE, BioLegend, USA). The purity of the lymphocyte gate was
evaluated by examining the distribution of cells in the coordinates of CD45 and CD14. The percentage
of positive cells was established based on the signal detected in samples stained with isotype-matched,
non-specific control antibodies. Three-colour immunofluorescence analyses were performed using a
FACSCalibur flow cytometer (BD Biosciences, USA) equipped with a 488 nm argon laser. A minimum
of 10,000 events were acquired and analysed using CellQuest Software (BD Biosciences, San Jose,
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CA, USA). The percentages of cells expressing specific surface markers were calculated. Background
fluorescence was determined, and the samples were gated to remove the cellular debris and include
only single cells.
2.4. Cytokine Quantification in the Plasma
Levels of IFN-γ, IL-6, IL-2, and IL-10 were determined in the plasma samples of IPAH patients
and of the control group. Cytokine concentrations were measured using commercially available
Quantikine ELISA kits from R&D Systems, Minneapolis, MN, USA. Human IFN-γ (sensitivity
<8 pg/mL), human IL-2 (sensitivity <7 pg/mL), human IL-6 (sensitivity 0.03–0.22 pg/mL), and human
IL-10 (sensitivity 0.03–0.17 pg/mL) were all purchased. The concentrations of cytokines were calculated
based on standard curves and presented in pg/mL. All ELISA assays were performed according to the
manufacturers’ instructions.
2.5. DNA Isolation and Calculation of EBV Load and Assessment of Anti-EBV Antibody Status
EBV loads were assessed as previously described [24]. DNA was isolated from 5 million PBMC
with the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions. The number of EBV-specific DNA copies in PBMC was calculated with the ISEX variant
of the EBV polymerase chain reaction (PCR) kit (GeneProof, Brno, Czech Republic). A specific
conservative DNA sequence for the EBV nuclear antigen 1 (EBNA-1) gene was amplified with real-time
PCR. The number of viral DNA copies per µL of eluent was adjusted for the efficiency of DNA isolation,
to be expressed as the viral DNA copy number per µg of DNA. All samples were examined in duplicate.
A corresponding negative control (DNA elution buffer) was also included. The concentration and
purity of the isolated DNA were verified with a BioSpec-nano spectrophotometer (Shimadzu, Kyoto,
Japan). Due to the detection threshold of 10 EBV DNA copies per µL, all samples below this threshold
were considered EBV negative (EBV(–)). PCR was performed with a 7300 Real Time PCR System
(Applied Biosystems, Foster City, CA, USA).
Additionally, anti-EBV serological status of the patients and the controls was assessed. EBV-specific
antibodies (Ab) were detected using commercial enzyme-linked immunosorbent assays (ELISA; IBL
International, Hamburg, Germany). IgA, IgM, and IgG antibody classes recognizing the early antigen
(EA), viral capsid antigen (VCA), and EBNA-1 have been measured. The specific signals were obtained
using ELISA Reader Victor TM3 (PerkinElmer, Waltham, MA, USA). Manufacturer-specified cut-offs
have been applied.
2.6. Patients’ Infection Status Assessment
All samples were tested individually for the presence of the common bacterial, viral, and
fungal pathogens. Bacterial (aerobic and non-aerobic) and fungal cultures were carried out under
standard conditions, and they yielded no pathogens [24]. The presence of the genetic material of
hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, Herpes simplex virus 1 and 2 (HSV-1 and -2),
cytomegalovirus (CMV), human papillomavirus (HPV), parvovirus B19, influenza virus, Borrelia
burgdorferi, Chlamydia trachomatis, Chlamydia pneumoniae, Mycobacterium tuberculosis, Toxoplasma gondii,
Ureaplasma spp., and Listeria spp. was determined with PCR-based tests, and none of the samples
gave a positive result [25,26]. Additionally, serological tests were performed for each patient and
for each pathogen separately: HCV, HBV, HIV, HSV-1 and -2, CMV, HPV, parvovirus B19, influenza
virus, Borrelia burgdorferi, Chlamydia trachomatis, Chlamydia pneumoniae, Mycobacterium tuberculosis,
Toxoplasma gondii, Ureaplasma spp. and Listeria spp.
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2.7. Statistical Analysis
Statistical significance was determined with a nonparametric Mann–Whitney test, and the p values
below 0.05 were considered significant. Correlations between EBV loads and several different variables
were assessed with Spearman’s rank test. p < 0.05 was considered significant. All calculations were
completed using GraphPad Prism 7 software (GraphPad Software, La Jolla, CA, USA).
3. Results
3.1. IPAH Patients Have a More Immunosuppressive Blood Cell Profile than Healthy Controls
PBMC isolated from patients suffering from IPAH were immunophenotyped, and the results
were compared to a corresponding age- and sex-matched patient group (age: IPAH: min 23, median
62, max 81; controls: min 39, median 56, max 77; 60% of females in both groups). Whilst there were
no significant changes in the fractions of total lymphocytes, B cells, and T cells (Table 1), we found
that several immune cell populations, including NK cells, CD4+, and CD8+ T lymphocytes were
significantly decreased in the blood of IPAH patients (Figure 1A–C, respectively). Levels of neutrophils
were slightly elevated in the IPAH group (Figure 1D), while proportions of Treg cells (Figure 1E) and
NKT-like cells (Figure 1F) were profoundly increased as compared to the controls.
Figure 1. Idiopathic pulmonary arterial hypertension (IPAH) patients display altered cellular
composition of the peripheral blood. Peripheral blood cells were immunophenotyped using flow
cytometry, and specific cell populations were quantified. Data are presented as percentage of total
leukocytes (CD45+ cells) or the absolute cell count in the blood for neutrophils. Graphs show comparison
of IPAH patients’ results and corresponding healthy controls. There is a significant decrease in the
proportions of (A) NK cells, as well as (B) CD4+ and (C) CD8+ T cells in the patients, as compared
to controls. Moreover, ratios of (D) neutrophils, (E) T regs, and (F) NKT-like cells are augmented.
Horizontal bars represent medians; boxes overlap 25th to 75th percentiles, and whiskers extend from
minimum to maximum. In the figure, * denotes p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001.
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Table 1. Results of the immunophenotyping of the peripheral blood and the plasma cytokine
determination of the IPAH patients and corresponding controls. Cells were enumerated and presented
either as No/vol or proportion of cells given as % of specific subpopulation within the leukocyte
(CD45+) population. Statistical significance was determined with nonparametric Mann–Whitney test;
p values below 0.05 were considered significant, and * denotes p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, and
**** p ≤ 0.0001.





Control 2.710 3.595 3.935 5.373 6.030 0.0378 (*)
IPAH 2.080 4.250 5.110 6.225 8.430
Lymphocytes
(103/mm3)
Control 1.530 1.988 2.535 2.785 3.070
NSIPAH 1.200 1.790 2.010 2.680 3.140
T lymphocytes (%) Control 60.63 65.52 68.08 70.93 74.49 NSIPAH 59.21 65.86 70.82 75.92 89.16
B lymphocytes (%) Control 6.04 9.86 11.40 12.37 16.90 NSIPAH 3.50 6.30 11.90 15.47 20.67
NK cells (%)
Control 12.16 13.54 14.43 17.22 19.34 0.0002 (***)
IPAH 3.99 8.05 11.23 13.57 20.43
NKT-like cells (%)
Control 1.15 2.42 3.27 3.51 4.92 0.0043 (**)
IPAH 0.67 2.92 5.23 7.45 10.94
CD4+
T lymphocytes (%)
Control 40.71 42.57 44.16 45.95 48.84 0.0190 (*)
IPAH 19.73 26.69 36.91 49.78 62.92
CD8+
T lymphocytes (%)
Control 29.33 31.22 34.74 37.25 39.60 0.0034 (**)
IPAH 9.19 18.73 28.30 33.01 59.29
CD4+/CD8+ ratio Control 1.030 1.188 1.290 1.433 1.570 NSIPAH 0.340 0.785 1.250 3.065 6.850
Treg (%) Control 3.15 5.49 7.37 8.33 10.15 <0.0001
(****)IPAH 5.94 9.31 11.21 14.73 23.81
PD1+ CD4+
T lymphocytes (%)
Control 2.65 3.83 5.35 6.64 7.69 <0.0001
(****)IPAH 8.00 11.73 15.49 21.46 38.24
PD-L1+ CD4+
T lymphocytes (%)
Control 0.98 1.30 1.71 2.52 3.49 <0.0001
(****)IPAH 1.43 8.83 17.84 23.91 37.42
PD-1+ CD8+
T lymphocytes (%)
Control 1.36 2.293 3.705 4.668 6.17 <0.0001
(****)IPAH 3.19 8.65 13.77 15.94 24.43
PD-L1+ CD8+
T lymphocytes (%)
Control 0.31 0.35 0.43 0.53 0.67 <0.0001
(****)IPAH 0.87 1.75 9.82 19.84 35.47
PD-1+
B lymphocytes (%)
Control 0.37 0.76 1.81 2.44 3.01 0.0011 (**)
IPAH 0.62 1.12 4.13 8.45 18.76
PD-L1+
B lymphocytes (%)
Control 0.07 0.14 0.20 0.28 1.03 <0.0001
(****)IPAH 0.14 2.37 14.20 17.39 21.05
IFN-γ (pg/mL) Control 0.606 1.233 2.336 3.329 4.378 <0.0001
(****)IPAH 5.579 6.092 7.044 9.738 23.300
IL-6 (pg/mL) Control 0.151 0.694 1.168 4.567 17.200 <0.0001
(****)IPAH 2.304 3.255 7.959 16.790 411.400
IL-10 (pg/mL) Control 2.775 3.045 4.081 4.800 6.157 NSIPAH 0.068 2.144 3.908 10.570 15.710
IL-2 (pg/mL) Control 0.478 0.978 2.360 3.563 7.155 <0.0001
(****)IPAH 9.387 11.380 13.800 31.850 150.100
Furthermore, percentages of T lymphocytes (both CD4+ and CD8+), as well as B cells expressing
PD-1 (Figure 2A–C) and PD-L1 (Figure 2D–F), were highly elevated in IPAH patients. A summary of
the blood cell immunophenotyping is presented in Table 1.
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Figure 2. PD-1 and PD-L1 are overexpressed on T and B cells of IPAH patients. Expression of PD-1
and PD-L1 was assessed on B cells, CD4+, and CD8+ T cells. CD4+ T cells, CD8+ T cells, and B cells
expressed (A–C) PD-1 and (D–F) PD-L1 markers at the significantly elevated levels in the IPAH patients’
blood. Horizontal bars represent medians; boxes overlap 25th to 75th percentiles, and whiskers extend
from minimum to maximum. In the figure, ** denotes p ≤ 0.01 and **** p ≤ 0.0001.
3.2. Proinflammatory Cytokine Levels in IPAH Patients’ Plasma are Elevated
Concentrations of several cytokines were measured in the plasma of the IPAH patients and of
the control group (Table 1). Here, patients suffering from IPAH had significantly increased levels of
pro-inflammatory cytokines: IFN-γ, IL-6, and IL-2 (Figure 3A–C, respectively). Interestingly, levels of
IL-10, an anti-inflammatory cytokine, were not significantly different between the patients and healthy
controls (Figure 3D).
Figure 3. Levels of proinflammatory cytokines are increased in the IPAH patients’ plasma, while
concentration of IL-10 remains unchanged. Plasma from IPAH patients and from healthy controls was
assayed for (A) IFN-γ, (B) IL-6, (C) IL-2, and (D) IL-10. Levels of IFN-γ, IL-6, and IL-2 were highly
increased in IPAH patients as compared to controls, and IL-10 was not statistically different between
those two groups. Horizontal bars represent medians; boxes overlap 25th to 75th percentiles, and
whiskers extend from minimum to maximum. Herein, **** denotes p ≤ 0.0001.
J. Clin. Med. 2020, 9, 1966 8 of 13
3.3. Haemodynamic Parameters of the IPAH Patients
IPAH patients were subjected to a series of tests assessing their haemodynamic parameters.
The patients were classified into one of four WHO functional classes, from class I—comprising the
least affected patients, to class IV—with the patients in the most severe condition [2]. There was one
patient belonging to class I (4%), nine patients from class II (36%), 12 patients from class III (48%), and
three patients presented characteristics of class IV (12%). The details of the haemodynamic parameters
are presented in Table 2.
Table 2. IPAH patient characteristics. Haemodynamic parameters, as well as BMI and levels of BNP of
25 IPAH patients are presented with the medians, minima, maxima, and 25th and 75th percentiles.
Parameter Minimum 25th Percentile Median 75th Percentile Maximum
BMI (kg/m2) 17.1 24.1 26.0 30.6 40.5
BNP (pg/mL) 210 666 1546 2129 10,144
6MWD (m) 136 315 374 454 556
PVR (mmHg x min-l) 158 473 651 894 1599
CI (l/min/m2) 1.43 2.01 2.60 2.92 3.75
CO (l/min) 2.11 3.99 4.46 5.40 6.42
RAP (mmHg) 2 4 9 12 23
MPAP (mmHg) 25 32 48 53 66
PASP (mmHg) 37 55 77 89 105
RVSP (mmHg) 42 52 76 82 96
PAWP (mmHg) 5 7 9 10 14
BMI—body mass index, BNP—B-type natriuretic peptide, 6MWD—6-min walking distance, PVR—pulmonary
vascular resistance, CI—cardiac index, CO—cardiac output, RAP—right atrial pressure, MPAP—mean
pulmonary artery pressure, PASP—pulmonary artery systolic pressure, RVSP—right ventricular systolic pressure,
PAWP—pulmonary artery wedge pressure.
3.4. EBV Status is Correlated with the Severity of Clinical Manifestation of IPAH and Expression of PD-1 on
CD4+ T Cells
Blood cells from IPAH patients and healthy controls were subjected to EBV load quantification.
Importantly, none of the patients nor the controls had a positive result with regard to common pathogen
infection, including hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, Herpes simplex virus 1 and 2
(HSV-1 and -2), cytomegalovirus (CMV), human papillomavirus (HPV), parvovirus B19, influenza
virus, Borrelia burgdorferi, Chlamydia trachomatis, Chlamydia pneumoniae, Mycobacterium tuberculosis,
Toxoplasma gondii, Ureaplasma spp., and Listeria spp. All samples from the healthy volunteers were
negative for EBV, while forty-four per cent (11 out of 25) of all IPAH patients were positive in the
EBV test. The viral load of the EBV-positive patients varied from 2.71 to 263.14, with the median of
44.34 EBV copy numbers per 1 µg of DNA. Analysis of correlation performed with the Spearman
test revealed that the EBV copy number was positively correlated with the severity of IPAH (WHO
functional class), r = 0.54, p = 0.005 (Figure 4A). Furthermore, a positive correlation was also found for
EBV load and the proportion of PD-1-expressing T helper lymphocytes: r = 0.56, p = 0.0035 (Figure 4B).
Interestingly, analysis of the serological status of the study participants revealed that all IPAH
patients with positive EBV DNA results had antibody titres indicating a viral reactivation, assessed
as described by De Paschale et al. [27] Samples of all of them were positive for anti-VCA IgM,
anti-VCA IgG, and anti-EBNA-1 IgG, while results of anti-EA IgM and anti-EBNA-1 IgM were negative.
Additionally, four patients had anti-EBNA-1 IgA. On the other hand, IPAH patients with negative
results of the EBV DNA test as well as all healthy controls had the anti-EBV status suggesting a past
EBV infection (anti-VCA IgM negative; anti-VCA IgG positive; anti-EBNA-1 IgG positive; anti-EA
IgM, IgG, and IgA negative; anti-VCA IgA negative; and anti-EBNA-1 IgA and IgM negative).
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Figure 4. Positive correlation between WHO functional class and the EBV copy number and EBV
load and the proportion of PD-1-expressing T helper lymphocytes. Weak, yet statistically significant
correlations have been observed for (A) WHO functional class and the EBV copy number (r = 0.54,
p = 0.005) as well as for (B) and EBV load and the proportion of PD-1-expressing CD4+ T cells (r = 0.56,
p = 0.0035). Correlation was assessed with the Spearman rank test, and no regression line is plotted on
the graphs.
4. Discussion
Development of PAH has been observed in patients with immunological disturbances such as
systemic sclerosis and chronically infected people such as those infected with HIV [28,29]. This suggests
that a prolonged, dysregulated inflammatory response may contribute to the pulmonary arterial
remodelling by increased vascular smooth muscle density, which is a hallmark of PAH [28]. In our
study, we found a weak but statistically significant correlation between the EBV load and the severity
of the clinical status of IPAH patients determined according to the WHO functional classification.
Furthermore, we also identified a correlation between the expression of PD-1 protein on CD4+ T
lymphocytes and the EBV load. We found that in comparison with healthy controls, IPAH patients had
decreased levels of CD4+ and CD8+ T lymphocytes and NK cells in the blood. Instead, levels of Tregs,
NKT-like cells and neutrophils were increased, and PD-1 and PD-L1 proteins were overexpressed on
both T and B cells.
It was reported previously that increased numbers of several immune cell types such as CD8+
cytotoxic T cells, CD4+ helper T cells, dendritic cells and macrophages were found in the lung tissue of
IPAH patients [7,8]. Simultaneously, IPAH patients had more regulatory T cells in the periphery [8],
and Ulrich et al. have additionally noted less cytotoxic T lymphocytes in the peripheral blood [30]. It is
now well established that a significant immune dysregulation is associated with IPAH [4]. Furthermore,
it has been suggested that a deficiency in NK and cytotoxic T cells might be linked with a poorer
prognosis for IPAH patients, resulting in their increased risk of death [9]. Similarly, in our cohort,
a significant decrease in the levels of NK cells, and CD8+ and CD4+ T cells was noted, which further
supports the fact that IPAH patients display a deficiency in the cytotoxic immune cell compartment
in the periphery. We also confirmed the observation of Austin et al. that the proportion of Treg cells
is elevated in IPAH patients [8]. Additionally, we identified NKT-like cells, known as an important
source of IFN-γ [31], as substantially upregulated in the blood of IPAH patients.
Activation of lymphocytes during infection or due to autoimmune disorders results in
overexpression of PD-1 protein on their surface [14,15,32]. In parallel, levels of PD-L1 are also
increased, which allows for regulation of the immune response to limit its overactivation and to protect
normal tissue function [15,32]. PD-1/PD-L1 interaction leads to inhibition of proliferation and impacts
the cytokine release triggered by activation of TCR [12]. An increase in PD-1 expression is also linked
with T-cell exhaustion, which is a T cell dysfunction characterized by altered proliferating abilities,
a changed cytokine profile and a loss of T cell effector function [33]. On the other hand, it has been
suggested that the PD-1/PD-L1 interaction may not necessarily lead to exhaustion but only indicates
constant immune cell activation due to chronic infection with maintained capability of cells to be
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activated and respond to various stimuli [34]. In fact, Utzschneider et al. have shown that a chronic
infection elicited T cells that were not functionally impaired and were able to transition into the memory
compartment [35]. Importantly, upregulation of PD-L1 does not fully parallel PD-1 expression due to
several factors, such as timing or cell type expressing PD-L1; therefore, a mere PD-L1 overexpression
does not indicate the immune system homeostasis [35,36]. Overexpression of PD-1 and PD-L1 induced
by EBV infection has been observed in various malignancies, including Hodgkin lymphoma and gastric
cancers [37,38]. We found that patients enrolled in our study had increased levels of PD-1 and PD-L1
on CD4+ and CD8+ T cells, as well as on B cells. Moreover, we found that expression of PD-1 on CD4+
T cells correlated with EBV load. Additionally, the clinical status of IPAH patients, assessed according
to the WHO functional classification, was also related to the EBV copy number, which suggests that
people suffering from IPAH might have major problems maintaining immune system homeostasis and
thus be more susceptible to EBV. Nonetheless, it remains to be elucidated whether overexpression of
PD-1/PD-L1 molecules on the surface of lymphocytes in the blood of the IPAH patients is associated
with their exhausted phenotype or that those cells remain fully functional.
The role of various proinflammatory cytokines in the development and progression of PAH has
been widely studied. Interestingly, Soon et al. reported that levels of IL-6, IL-8, and IL-12 predicted
survival of patients and the level of IL-6 has been a better predictive marker than standard methods,
such as six-minute walk distance and haemodynamic parameters [6]. Of note, in our study, plasma
levels of IFN-γ, IL-6, and IL-2, cytokines related to the inflammatory state of the immune system, were
highly elevated in the samples derived from IPAH patients as compared to healthy controls, whereas
there was no correlation of the cytokine levels and EBV loads.
Some viruses may influence blood vessel remodelling, and development of atherosclerosis or
hypertension [18,39]. Severe pulmonary hypertension is one of the cardiovascular complications of
HIV infection [16]. Other viruses such as cytomegalovirus, EBV, or Herpes simplex type 1, as well
as Helicobacter pylori and Mycoplasma pneumonia, have been found to contribute to development
of atherosclerosis [39]. Moreover, the contribution of herpesviruses to development of PAH has
been already examined. HHV-8, a vasculotropic virus, has been implicated by some authors in the
development of primary pulmonary hypertension [18,19]. Other studies, however, do not confirm a
link between HHV-8 infection and PAH [20,21,40]. Furthermore, EBV has been reported among factors
contributing to PAH development [17,41,42] However, no studies have investigated a potential link
between EBV infection and severity of the IPAH patients’ condition.
Limitations of the Study
In our study, we included a carefully chosen group of newly diagnosed IPAH patients with
strict inclusion criteria, such as no infection three months prior to the study, no immunomodulatory
treatment, no allergy, etc. Since IPAH is a rare disease, we only found 25 patients fulfilling the criteria,
and we deeply analysed samples obtained from those patients and matched them with other clinical
values such as haemodynamic parameters. A larger study group could deliver more statistically
significant correlations or differences between IPAH patients and healthy controls. Additionally,
longitudinal studies on how the WHO functional class of the study participants would change over
time and whether the progression towards higher classes would correlate with the EBV loads in the
patients would deliver an important information. Indeed, we plan to follow the patients described in
this study and add the new data on how and whether the IPAH status changes will be reflected by the
changes in the EBV loads.
5. Conclusions
Our observations shed light on the impact of EBV on the clinical status of IPAH patients.
We speculate that a viral reactivation may appear due to the immune system imbalance typically
observed in IPAH patients. However, it requires further studies to establish whether infection with
EBV may also predispose people to develop pulmonary arterial hypertension—as it is observed for
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HIV [16]. We rather hypothesise that the loss of immune homeostasis seen in IPAH patients contributes
to a greater susceptibility of those people to EBV reactivation and possibly also de novo infection,
which in turn leads to even more severe immune system dysregulation paralleled by aggravation of
the IPAH symptoms.
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